secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-06-23T20:05:18+00:00
Accession:  0001171843-26-004253
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika shareholders approve share reserve increases for equity plans at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2017 Omnibus Incentive Plan, increasing reserved shares from 5,760,000 to 6,110,000 (350,000 share increase).
- Stockholders approved amendment to 2021 Employee Stock Purchase Plan, increasing reserved shares from 200,000 to 400,000 (200,000 share increase).
- Directors Gary P. Fischetti, John B. Henneman III, and Stephen D. Griffin elected as Class III directors until 2029 annual meeting.
- Ratification of Deloitte & Touche as independent auditor for FY2026 passed: 11,136,590 for, 24,966 against, 34,111 abstain.
- Advisory say-on-pay vote passed: 8,268,676 for, 1,093,946 against, 31,179 abstain; 1,801,866 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004253/0001171843-26-004253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004253/f8k_062326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer